The goal of the project, to be implemented by JSC Grindeks, is to develop new technologies for acquisition of two oncology preparations – Pazopanib and Nilotinib. Research will be carried out by scientific institution selected in an open tender – Latvian Institute of Organic Synthesis. Implementation of the project is anticipated for 27 months, and the total cost of it – 265 188.45 EUR, including the contribution from the ERDF – 142 456.60 EUR.

The goal of this EU fund programme is to support research that contributes to achievement of the Latvian smart specialization strategy goals, development of scientific and technological human capital and the creation of new knowledge to improve the competitiveness of the economy. Supported are the research projects which contribute to Latvian smart specialization strategies – economic transformation directions and implementation of growth priorities and development of the following specialization areas: knowledge-based bio-economy, bio-medicine, medical technology, biotechnology and bio-pharmacy, intelligent materials, technology and engineering, smart energy, and information and communication technologies.

CFCA is concluding agreements with scientific institutions and companies whose projects were approved after evaluation. There were submitted a total of 309 projects within the program, amounting at 145 057 174.09 EUR. Throughout a selection process 74 project ideas that initially received conditional approval were directed further. Currently, after receiving clarifications, 48 projects have been confirmed, but agreements are concluded for the implementation of the first four projects.

Information on the results of the selection – all the final approvals that have been granted to projects – is published on the CFCA website, on announced selection section.

Information about all the CFCA announced selections is available on CFCA website, on Announced selections section.